Skip to main content

Market Overview

Jefferies Downgrades Salix Pharmaceuticals As Raised Bid By Valeant Appears Final


In a report published Wednesday, Jefferies analyst David Steinberg downgraded the rating on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) from Buy to Hold, but raised the price target from $149.00 to $173.00.

In the report, Jefferies noted, "After a litany of suitors cast their bids, SLXP has agreed to be acquired by VRX in an all-cash transaction for $173. Post VRX's initial proposal of $158, we had thought there was a possibility another bid might emerge and indeed ENDP gave it a try. However, given VRX's improved terms and the fact that ENDP rescinded its final offer, we view the likelihood of a successful tender close on or near April 1 as very high. We thus downgrade SLXP from Buy to Hold."

Salix Pharmaceuticals closed on Tuesday at $172.48.

Latest Ratings for SLXP

Mar 2015JefferiesDowngradesBuyHold
Feb 2015Cantor FitzgeraldDowngradesBuyHold
Feb 2015UBSDowngradesBuyNeutral

View More Analyst Ratings for SLXP
View the Latest Analyst Ratings


Related Articles (SLXP)

View Comments and Join the Discussion!

Posted-In: David Steinberg JefferiesAnalyst Color Downgrades Analyst Ratings

Latest Ratings

PBTruist SecuritiesMaintains88.0
CFRTruist SecuritiesMaintains111.0
FANGTruist SecuritiesMaintains105.0
SBNYCredit SuisseMaintains250.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at